Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6090 Combinations in Advanced Lung Cancer
NCT07472647Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07472647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472647.